Verona Pharma plc — Director's Dealing 2024

Aug 10, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Verona Pharma plc (VRNA)
CIK: 0001657312
Period of Report: 2024-08-07

Reporting Person: Hahn Mark W (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-08-07	Ordinary Shares	A	800000	—	Acquired	15654488	Direct
2024-08-07	Ordinary Shares	F	314800	$2.62	Disposed	15339688	Direct

Footnotes

F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F2: Represents an award of Ordinary Shares upon vesting of Performance Restricted Share Units in connection with the Issuer's first commercial sale of ensifentrine.

F3: Represents the number of Ordinary Shares withheld to satisfy the tax withholding obligation in connection with the vesting of the Performance Restricted Share Units described in footnote 2 above.

F4: The price reported represents the closing price of the Issuer's ADSs on the Nasdaq Stock Market LLC on August 6, 2024 divided by eight (8).

F5: Consists of (i) 2,825,000 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 353,125 ADSs); and (ii) 12,514,688 Ordinary Shares underlying 1,564,336 ADSs.